ABRAXAS1 and prostate cancer: Here, BRCA1, BRCA2, PALB2, FAM175A, and BARD1 were all seen to be synthetic lethal with PARG following siRNA mediated depletion and inhibition of PARG activity, each gene has been associated with breast cancer and ovarian cancer [47], [48], [49], [50], as well as prostate cancer (BRCA1, BRCA2, PALB2) [50], [51], [52], [53] and pancreatic cancer (PALB2, BRCA1, BRCA2) [54], [55], [56], [57] thus PARG inhibition may have clinical potential in some of these patients.